-
PDF
- Split View
-
Views
-
Cite
Cite
Masud Husain, Brain publishes clinical trials, Brain, Volume 149, Issue 10, October 2026, Pages 3291–3292, https://doi.org/10.1093/brain/awag296
Close - Share Icon Share
Some of our readers have expressed their surprise—and delight—to learn that Brain publishes clinical trials. We do! And we’d like to encourage more manuscripts in this category to be submitted, including experimental medicine trials. High-quality clinical trials complement the journal's traditional strength in disease mechanisms by completing the translational arc: from understanding the causes of neurological and psychiatric disorders to demonstrating how that knowledge can improve patients’ lives. For this reason, we are willing to expedite review of trial manuscripts if authors request this.
Unlike observational or mechanistic studies, a well-conducted trial can establish whether an intervention can lead to significant benefits for patients, and at what cost in terms of adverse effects. In this way trials can directly change clinical practice. At Brain, we welcome standard randomized clinical trials (RCTs) but also other designs, including n-of-1 studies conducted across multiple patients.1 Trials can provide some of the strongest evidence for causality and test whether biological understanding is therapeutically meaningful. A disease mechanism may appear compelling experimentally, but a trial tests the tougher question of whether manipulating that mechanism makes patients any better. In this regard, negative trials can also be scientifically valuable. They can overturn plausible hypotheses, prevent ineffective or harmful treatments from being adopted, and redirect research towards more promising mechanisms or patient subgroups. Brain therefore welcomes trials with negative findings.
Trials often yield much more than a treatment-effect estimate. Embedded imaging, biomarkers, genetics, digital measures and cognitive phenotyping can reveal mechanisms of response, predictors of outcome and reasons for treatment failure. We also appreciate that they can help to define clinically meaningful outcomes. Trials challenge us all to confront what actually matters to patients—function, disability, cognition, quality of life, survival—not merely statistically significant changes in laboratory measures. They can also influence clinical guidelines, regulation and health policy, including assessments of cost-effectiveness. But we are also aware that trials help to connect basic and clinical neuroscience. They can demonstrate that discoveries about genes, molecules, circuits and disease mechanisms can progress from explanation to therapeutic intervention. In this way, they signal maturity of a research field.
This year Brain has published a number of trials which illustrate some of these points. In their study, Yiangou and colleagues2 asked an important mechanistic question about idiopathic intracranial hypertension (IIH): Why do patients often experience headaches that seem remarkably like migraine? They tested whether calcitonin gene-related peptide (CGRP), now established as a key mediator of migraine, can directly provoke the characteristic headache of IIH. In a randomized, double-blind, placebo-controlled crossover study, women with IIH and no prior history of migraine received intravenous CGRP or placebo on separate visits. CGRP provoked a typical IIH headache with migraine-like features in 71% of participants, compared with only 18% after placebo, and overall headache intensity was also greater after CGRP.
A particularly interesting aspect of the study is that the investigators simultaneously measured intracranial pressure (ICP) and cerebrovascular physiology. CGRP did not increase mean ICP, despite reliably causing headache. It did, however, significantly increase ICP pulse amplitude, a measure related to intracranial compliance, while producing the expected systemic and cerebral vascular effects, including increased heart rate and reduced middle cerebral artery blood velocity. This separates, at least partly, the generation of headache from simply having a higher static intracranial pressure. It suggests that headache in IIH may depend on activation of CGRP-sensitive trigeminovascular pathways and possibly altered intracranial pulsatility or compliance, rather than being merely the direct consequence of elevated mean ICP. The broader significance is therefore both conceptual and therapeutic. IIH headache has traditionally been regarded principally as a secondary consequence of raised intracranial pressure, whereas these results provide experimental evidence that it shares an important molecular mechanism with migraine, helping to explain why the clinical phenotype is so often migraine-like and thereby provides a rational basis for trials of CGRP-pathway antagonists or monoclonal antibodies specifically for IIH headache.
In a different clinical trial, Moser and colleagues3 tested whether propionic acid, a short-chain fatty acid produced by gut bacterial fermentation of dietary fibre, might have therapeutic effects in multiple sclerosis (MS). Propionic acid is of particular interest because circulating and faecal levels appear to be reduced in people with MS, and previous uncontrolled studies had suggested immunological and clinical benefits from supplementation. In the MADAI phase 2b trial, 101 adults with clinically stable MS were randomized 2:1, double-blind, to propionic acid 500 mg twice daily or placebo for 90 days, in addition to their existing disease-modifying therapy. The prespecified primary outcome was serum neurofilament light chain (sNfL), a sensitive biomarker of neuroaxonal injury.
The principal finding was a 17.9% reduction in sNfL on propionic acid, whereas the change in the placebo group was not significant. The adjusted between-group difference at 90 days was statistically significant, although modest. Propionic acid was well tolerated, with no treatment-related serious adverse events. Although there was a suggestion of improvement in motor fatigue, none of the secondary clinical outcomes showed a significant between-group treatment effect. The significance of the study is that it provides the first randomized placebo-controlled evidence that supports a potential biological effect of propionic acid supplementation in MS. However, caution is required as this was a small, single-centre, 90-day study whose primary positive result was a biomarker, with no demonstrated effect on disability, cognition, relapse rate or quality of life. Follow-up studies are clearly required.
In this issue of Brain, Régis and colleagues4 address a different therapeutic problem in severe, drug-refractory essential tremor. Many patients with this condition have disabling bilateral tremor. Bilateral lesioning of the thalamic ventral intermediate (VIM) nucleus has raised concerns about postoperative dysarthria, gait disturbance and disequilibrium. In this prospective, single-arm phase 2 trial, 33 patients who had previously undergone unilateral VIM gamma knife radiosurgery received a staged second-side procedure, on average 28.7 months later. Crucially, patients with significant pre-existing speech, gait or balance problems were excluded. The primary end-point was safety, assessed alongside detailed measures of tremor, disability, quality of life, cognition, speech, gait, posture and MRI over 12 months.
The reported clinical improvements were substantial. Overall tremor severity fell by 58.5%, disability by 84.8%, and functional impact by 68.6%. Among the 29 of 33 patients who responded, tremor in the newly treated upper limb improved by an average of 74.4%, and quality of life improved significantly. Equally important, there was no significant deterioration in cognition, speech, gait or balance at the group level. Only one major treatment-related adverse event was reported: a patient developed sensory ataxia and dysarthria associated with an excessive radiation response 11 months after the second procedure. Thus, in this selected population, bilateral treatment did not produce the high frequency of disabling bilateral neurological complications that has traditionally made clinicians cautious about bilateral thalamic lesioning. The significance of this study is that staged bilateral gamma knife thalamotomy may provide a viable non-invasive option for patients with disabling bilateral essential tremor who are unsuitable for, or do not want, deep brain stimulation.
These examples showcase the wide range of trial designs, including experimental medicine as well as more conventional RCTs, that we publish and welcome at Brain. If you have any questions regarding the suitability of your study, please contact us. We can also consider your manuscript for expedited review, on request.